The Effects of Rotator Interval Hydro-dissection in Primary Adhesive Capsulitis.

Adhesive Capsulitis of Shoulder Clinical Trial

Official title:

The Effects of Rotator Interval Hydro-dissection in Primary Adhesive Capsulitis. A Two-arm Double-blind Randomised Controlled Trial

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05977985
• Other study ID #: 2023630-12612
• Status: Not yet recruiting
• Phase: Phase 4
• Start date: August 1, 2023
• Est. completion date: July 1, 2025

Study information

• Verified date: July 2023
• Source: University of Malaya
• Contact: Richard Teo
• Email: richardskteo[@]ummc.edu.my
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Adhesive capsulitis (AC) is a significant cause of chronic shoulder pain and disability. Non-surgical option consisting of intraarticular corticosteroid (IA CS) injection with structured physiotherapy (PT) is the current standard of care. More recent randomized controlled trials have found that rotator interval (RI) hydro-dissection approach leads to better improvement in pain as compared to IA approach. Despite being non-inferior to surgical management, long-term outcome studies of patients treated with IA CS injection and PT have shown that patients only achieve satisfactory outcomes in 72.3% of patients after a mean symptom duration of 41.8 months. Furthermore, CS injections are associated with significant systemic and local adverse effects such as Cushing syndrome, osteopenia/ osteoporosis, infection, and hyperglycemia. In recent years, dextrose injection has emerged as an effective alternative to CS-based injections to treat chronic painful musculoskeletal conditions such as chronic low back pain, peripheral nerve entrapment and lateral epicondylitis.

The investigators aim to study the effects of RI hydro-dissection with dextrose 5% (D5%) on pain relief, shoulder ROM and shoulder function in patients with primary AC.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 60
• Est. completion date: July 1, 2025
• Est. primary completion date: July 1, 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 35 Years to 65 Years

Eligibility

Inclusion Criteria:

• patients with primary adhesive capsulitis

• aged 35 to 65 years of age

• duration of symptoms in between 3 to 18 months

• limitation in flexion, abduction, and external rotation greater than 30 degrees compared to normal

• limitation in internal rotation with hand to back shoulder test below L4

Exclusion Criteria:

• diagnosis of connective tissue disease or inflammatory arthritis

• history of surgery to the affected shoulder

• history of shoulder dislocation/ fracture

• neurological weakness of the affected upper limb

• ultrasound findings of rotator cuff or LHBT tendinopathy

• plain radiographs showing significant glenohumeral joint osteoarthritis (Kallgren-Lawrence grade 3 or 4)

• other sources of chronic pain

• bilateral adhesive capsulitis

• history of pain intervention to the shoulder joint in the past 3 months

• allergic reaction to local anesthetic agent

Related Conditions & MeSH terms

• Adhesive Capsulitis of Shoulder
• Bursitis

Intervention

Drug:
• Rotator interval hydro-dissection with dextrose 5%
Single injection of 20ml dextrose 5% into the rotator interval around the long head biceps tendon under ultrasound guidance using a 11-14 Hz frequency linear probe
• Rotator interval hydro-dissection with corticosteroid solution
Single injection of 20ml corticosteroid solution (1 ml triamcinolone 40 mg/ml + 19 ml saline 0.9%) into the rotator interval around the long head biceps tendon under ultrasound guidance using a 11-14 Hz frequency linear probe

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
University of Malaya

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Adverse events	Adverse events during or after injection	from time to injection up till 1 week post injection
Primary	Shoulder pain	Shoulder pain based on Shoulder Pain and Disability Index (SPADI) pain scale. The SPADI pain scale ranges from 0 to 50, with higher score indicating greater level of pain.	1 week, 4 weeks and 12 weeks post injection
Secondary	Shoulder range of motion	Shoulder range of motion in flexion, abduction, external rotation, internal rotation	4 weeks and 12 weeks post injection
Secondary	Shoulder function	Shoulder function based on Shoulder Pain and Disability Index (SPADI) disability scale. The SPADI disability scale ranges from 0 to 80, with higher score indicating greater level of disability.	4 weeks and 12 weeks post injection